While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Contacts: For investor inquires: Aratana Therapeutics, Inc. Craig Tooman ; (913) 353-1026 For media inquiries: Tiberend Strategic Advisors, Inc. Andrew Mielach ; (212) 375-2694 To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/aratana-therapeutics-announces-positive-top-line-results-from-at-001-pivotal-field-study-in-client-owned-dogs-with-osteoarthritis-300012240.html SOURCE Aratana Therapeutics, Inc. Related Links http://www.aratana.com